Improved Diagnostics And Genomics Will Broaden Treatment Access
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
06 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$16.09
54.4% undervalued intrinsic discount15 Aug
US$7.34
1Y
-38.4%7D
5.2%